Targeted therapies in squamous cell carcinoma of the head and neck (Q37373573)

20 August 2017

1 reference

title

Targeted therapies in squamous cell carcinoma of the head and neck (English)

1 reference

20 August 2017

main subject

squamous cell carcinoma

1 reference

Kathryn A Gold

1 reference

20 August 2017

Ho-Young Lee

series ordinal

1 reference

20 August 2017

Edward S Kim

series ordinal

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 March 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

115

1 reference

20 August 2017

1 reference

20 August 2017

page(s)

922-935

1 reference

Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

Role of angiogenesis in tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

The chemoradiation paradigm in head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Evidence for a causal association between human papillomavirus and a subset of head and neck cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Chemoprevention of lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Epidermal growth factor receptor inhibition strategies in oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Epidermal growth factor receptor (EGFR) signaling in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Differential expression of epidermal growth factor receptor in human head and neck cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Novel therapeutics for head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Tumor angiogenesis and accessibility: role of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

The IGF‐1 receptor in cancer biology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Growth factor receptor interplay and resistance in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Src as a potential therapeutic target in non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24123

7 January 2021

Identifiers

DOI

10.1002/CNCR.24123

1 reference

20 August 2017

1 reference